Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 7,968 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 7,968 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $382,464.00. Following the completion of the transaction, the chief executive officer now directly owns 581,584 shares of the company’s stock, valued at approximately $27,916,032. This represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Trading Down 8.3 %

Shares of TWST opened at $38.96 on Friday. The firm has a 50-day simple moving average of $43.90 and a two-hundred day simple moving average of $45.88. Twist Bioscience Co. has a 1-year low of $18.80 and a 1-year high of $60.90.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the stock. SageView Advisory Group LLC purchased a new position in shares of Twist Bioscience in the first quarter valued at approximately $1,144,000. Susquehanna Fundamental Investments LLC acquired a new position in Twist Bioscience during the 1st quarter worth $300,000. Sei Investments Co. grew its stake in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after purchasing an additional 55,124 shares in the last quarter. Silvercrest Asset Management Group LLC increased its holdings in Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the period. Finally, Principal Financial Group Inc. grew its position in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on TWST. Evercore ISI boosted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird boosted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.